GENNIEFY
Market News
Latest financial news and analysis from global markets
MSFT
Microsoft Appears to Have Made More Concessions Than Gains Under Amended Deal With OpenAI, UBS Says
Microsoft (MSFT) appears to have made more concessions than gains under the recently amended agreeme
AMZN
Microsoft Appears to Have Made More Concessions Than Gains Under Amended Deal With OpenAI, UBS Says
Microsoft (MSFT) appears to have made more concessions than gains under the recently amended agreeme
BTCUSDT
Solana News: SOL Ends Lower as Traders Turn Bearish, Foundation Prepares for Quantum Risk
Solana ended the week lower as traders turned more cautious, with macro jitters weighing on risk appetite.
SOLUSDT
Solana News: SOL Ends Lower as Traders Turn Bearish, Foundation Prepares for Quantum Risk
Solana ended the week lower as traders turned more cautious, with macro jitters weighing on risk appetite.
LC
LendingClub Is Changing Its Name to Happen Bank, as It Makes Progress on Its Medium-Term Growth Plan. Is the Stock a Buy?
LendingClub has come a long way over the past five years.
AAPL
Apple Likely to Post Slight Fiscal Q2 Upside, 'Solid' June Guidance, UBS Says
Apple (AAPL) is likely to post a slight upside to fiscal Q2 estimates driven by iPhone and Mac deman
NVDA
Lower Mortgage Rates in 2026: A Downsizing Opportunity Retirees Shouldn't Ignore
If you're thinking of relocating or downsizing, low rates can help.
INTC
Lower Mortgage Rates in 2026: A Downsizing Opportunity Retirees Shouldn't Ignore
If you're thinking of relocating or downsizing, low rates can help.
MSFT
Semiconductor Sell-Off Pushes S&P 500, Nasdaq Lower
US equity indexes were mixed in Tuesday's midday trading, with the S&P 500 and the Nasdaq Composite
PFE
Should You Buy, Sell, or Hold Pfizer at $27?
The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question mark.
WMT
This Beaten‑Up Dividend Stock Is Ready for a Rebound Few See Coming
Target's new CEO has been working on turning around the business, and early indications suggest things are going in the right direction.
NVDA
Should You Buy, Sell, or Hold Pfizer at $27?
The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question mark.